Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections

Keyphrases

• Staphylococcal Infections 100%
• Systemic Treatment 100%
• Liposomal 100%
• Mupirocin 100%
• Staphylococcus Aureus 30%
• Methicillin-resistant S. Aureus 30%
• Antibiotics 15%
• Invasive Infection 15%
• Murine Model 7%
• Therapeutic Efficacy 7%
• Infection Rate 7%
• Topical Administration 7%
• Neutropenic 7%
• Clinical Application 7%
• Clinical Development 7%
• Mode of Action 7%
• Phagocytosis 7%
• Therapeutic Approaches 7%
• Free Drug 7%
• Enhanced Delivery 7%
• Increased Incidence 7%
• PEGylated 7%
• Nanoliposomes 7%
• Resistant Strains 7%
• Machine Learning Approach 7%
• Antimicrobial Activity 7%
• Intracellular Niche 7%
• Infected Macrophages 7%
• Prolonged Half-life 7%
• Rapid Degradation 7%
• S. Aureus Infection 7%
• Antibiotic Distribution 7%
• Plasma Instabilities 7%
• S. Aureus Bloodstream Infection 7%
• Liposomal Formulation 7%
• Liposomal Encapsulation 7%
• Murine Lung Infection Model 7%
• Computational Prediction 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Staphylococcal Infection 100%
• Systemic Treatment 100%
• Mupirocin 100%
• Staphylococcus Aureus 69%
• Infection 38%
• Meticillin 30%
• Lung Infection 7%
• Elimination 7%
• Combination Therapy 7%
• Liposome 7%
• Bloodstream Infection 7%
• Antimicrobial Agent 7%

Immunology and Microbiology

• Staphylococcus Aureus 100%
• Mupirocin 100%
• Blood Plasma 15%
• Macrophage 7%
• Phagocytosis 7%
• Metabolite 7%
• Antimicrobial Activity 7%
• Antimicrobial Agent 7%